Neuland Laboratories Ltd Share Price (NEULANDLAB)

Neuland Laboratories NLL, a private limited company founded in 1984, manufactures bulk drugs, such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin, which are exported to more than 35 countries. To part finance capacity expansion and diversify its product-mix, NLL made an initial public offering in 1994 for Rs 5.69 crores. The Research & Development has developed a process to manufacture Oflaxacin for Regulatory Markets, and the Pashamylaram unit received USFDA approval for Rantidine Hydrochloride Form. During the years 1992-2000 the company introduced Itraconazole, an antifungal drug, Ipratropium Bromide, an antiasthmatic drug, Mirtrazapine, an antidepressive drug, and Ramipril, a cardiovascular drug, while in 2001 it increased its capacity of Ciprofloxacin and Ranitidine with financial assistance from IDBI of Rs.65 lacs. In 2002, it commenced production of Ramipril and in 2003 of Citalopram Hydrobromide, Pirbuterol Acetate, Levofloxacin and Levetiracetam. Furthermore, Neuland Laboratories Ltd has a subsidiary in Delaware USA and in Japan (2008-2009). Neuland Laboratories NLL is thus well-positioned in the bulk drugs market and is continuously striving to expand its product mix with the help of innovation in research and development.

Revenue: ₹328.36Cr as on March 2025 (Q4 FY25)
Net Profit: ₹27.81Cr as on March 2025 (Q4 FY25)
Listing date: 17 May, 1995
Chairperson Name: D Saharsh Rao